Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005227235
Fri, 19.12.2025
Biotest AG
PRESS RELEASE
Biotest announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt)
Fesilty™ (fibrinogen, human-chmt) approved by the U.S. Food and Drug Administration (FDA)
This new fibrinogen product was developed and is manufactured by Biotest AG and will be commercialized in the U.S. by Grifols
U.S. market entry planned in [ … ]
Thu, 13.11.2025
Biotest AG
PRESS RELEASE
Biotest obtains approval for new human fibrinogen Prufibry® in Germany
New life-saving therapy for patients with congenital and acquired fibrinogen deficiency
Clinical studies demonstrate efficacy and safety in bleeding control and surgical settings
Important expansion to Biotest’s intensive care and coagulation factor portf [ … ]
Fri, 07.11.2025
Biotest AG
PRESS RELEASE
Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A.
Renewed request for convocation dated 21 October 2025
Resolution on the change of legal form to a partnership limited by shares (KGaA)
Dreieich, 7 November 2025. Biotest AG announces that, after careful consideration, the Management Bo [ … ]
Thu, 23.10.2025
Biotest AG
PRESS RELEASE
Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
Withdrawal of the convocation request as of 1 August 2025 by Grifols S.A.
Dreieich, 23 October 2025. Biotest AG hereby announces that its majority shareholder, Grifols S.A., Barcelona, Spain, informed the Management Board on 22 October 2025 that it [ … ]
Thu, 09.10.2025
Biotest AG
PRESS RELEASE
Biotest’s Yimmugo® launches in the United States
Dreieich, Germany, October 9, 2025. Biotest AG, a specialist in innovative haematology, clinical immunology and intensive care medicine and part of Grifols, a global healthcare company and leading producer of plasma-derived medicines, proudly announces the official launch of Yi [ … ]
Fri, 19.09.2025
Biotest AG
PRESS RELEASE
Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A.
Resolution on the change of legal form to a partnership limited by shares (KGaA)
Dreieich, 19 September 2025. Biotest AG announces that, after careful consideration, the Management Board has deemed admissible the request received in writing fro [ … ]
Mon, 04.08.2025
Biotest AG
PRESS RELEASE
Biotest AG receives a request from Grifols S.A. to convene an extraordinary general meeting
Management Board examines whether the request meets the legal requirements
Proposed resolution on the conversion of Biotest AG into Biotest GmbH & Co. KGaA
Dreieich, 4 August 2025. Biotest AG hereby announces that its majorit [ … ]
Wed, 02.07.2025
Biotest AG
PRESS RELEASE
Biotest AG: Annual General Meeting approves dividend distribution
Distribution of € 0.04 per preference share for the year 2024
Broad majority in the vote in line with the management's proposals
Dreieich, 02 Juli 2025. At the Annual General Meeting on Juli 2, 2025, the shareholders of Biotest AG resolved to distribute a dividen [ … ]
Mon, 23.06.2025
Biotest AG
PRESS RELEASE
Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine
The data will also be presented tomorrow as part of three abstracts at the currently ongoing International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress
The Phase III AdFIrst study met its primary endpoint demonst [ … ]
Mon, 12.05.2025
Biotest AG
PRESS RELEASE
Biotest confirms Guidance for 2025
Sales increases for human albumin and Yimmugo
First quarter in line with expectations
Dreieich, May 12, 2025. In the first quarter of fiscal year 2025, the Biotest Group generated sales of € 124.2 million. This represents a decrease of € 91.0 million or 42.3 % compared to sales of € 215.2 mi [ … ]
